TY - JOUR T1 - Interpreting the ASTEROID Trial JF - Cleveland Clinic Journal of Medicine JO - Cleve Clin J Med SP - 937 LP - 944 VL - 73 IS - 10 AU - Ilke Sipahi AU - Stephen J. Nicholls AU - E. Murat Tuzcu AU - Steven E. Nissen Y1 - 2006/10/01 UR - http://www.ccjm.org/content/73/10/937.abstract N2 - The ASTEROID trial (JAMA 2006; 295:1556–1565) showed that very intensive statin therapy with rosuvastatin 40 mg once daily results in highly significant regression of coronary atherosclerosis as assessed by serial intravascular ultrasonography (IVUS). The mean low-density lipoprotein cholesterol (LDL-C) level achieved with this regimen was 61 mg/dL, and the mean high-density lipoprotein cholesterol (HDL-C) level increased by 15%. While the merits of concomitant LDL-C-lowering and HDL-C-raising therapies remain to be determined, the results of the ASTEROID and other recent trials suggest that the optimal strategy for lipid-lowering in patients with coronary artery disease is to try for the lowest LDL-C level that can be attained without adverse effects. ER -